Format

Send to

Choose Destination
Vaccine. 2016 Nov 21;34(48):5845-5854. doi: 10.1016/j.vaccine.2016.10.040. Epub 2016 Oct 25.

Influenza Vaccine Research funded by the European Commission FP7-Health-2013-Innovation-1 project.

Author information

1
Department of PharmacoTherapy, Epidemiology & Economics, University of Groningen, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands. Electronic address: h.liu@rug.nl.
2
Department of Pharmaceutical Technology and Biopharmacy, University of Groningen, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands.
3
Department of Medical Microbiology, University Medical Center Groningen, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands.
4
Department of PharmacoTherapy, Epidemiology & Economics, University of Groningen, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands.
5
European Vaccine Initiative (EEIG), Im Neuerheimer Feld 307, 69120 Heidelberg, Germany.
6
Erasmus University Medical Center Rotterdam (EMC), Dr. Molewaterplein 50, 3015 CE Rotterdam, The Netherlands.
7
The Institute of Virology and Immunology (IVI), Sensemattstrasse 293, CH-3147 Mittelhäusern, Switzerland.
8
iQur Limited, London Bioscience Innovation Centre, 2 Royal College Street, NW1-0NH London, United Kingdom.
9
Department of PharmacoTherapy, Epidemiology & Economics, University of Groningen, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands. Electronic address: e.hak@rug.nl.

Abstract

Due to influenza viruses continuously displaying antigenic variation, current seasonal influenza vaccines must be updated annually to include the latest predicted strains. Despite all the efforts put into vaccine strain selection, vaccine production, testing, and administration, the protective efficacy of seasonal influenza vaccines is greatly reduced when predicted vaccine strains antigenically mismatch with the actual circulating strains. Moreover, preparing for a pandemic outbreak is a challenge, because it is unpredictable which strain will cause the next pandemic. The European Commission has funded five consortia on influenza vaccine development under the Seventh Framework Programme for Research and Technological Development (FP7) in 2013. The call of the EU aimed at developing broadly protective influenza vaccines. Here we review the scientific strategies used by the different consortia with respect to antigen selection, vaccine delivery system, and formulation. The issues related to the development of novel influenza vaccines are discussed.

KEYWORDS:

Broadly protective; Correlates of protection; EU consortia; Influenza; Vaccines

PMID:
27793486
DOI:
10.1016/j.vaccine.2016.10.040
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center